方达医药新闻资讯

Philadelphia, PA – June 4, 2016: Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, today announced that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma. The acquisition includes Sun Pharma’s oral solid dosage manufacturing facilities in Philadelphia, PA, and Aurora, IL and 15 related pharmaceutical products (the “Acquired Products”). Terms of the transaction were not disclosed. Frontida has been founded to provide Contract Manufacturing and Co-development services for Frontage’s large base of pharmaceutical industry clients and partners, and will utilize the facilities as its primary base of operations.

Boston, US & London, UK, May 19, 2016 – Frontage Laboratories, a full-service contract research organization (CRO) with labs in the United States and China, has selected IDBS E-WorkBook 10 to be deployed across its laboratory facilities. In addition to serving as the global electronic lab notebook (ELN), the Pennsylvania-based bioanalytical (BA) laboratory is implementing the IDBS BA solution as its lab execution system. These workflow configurations will ensure end-to-end compliance, quality, and traceability across the GLP laboratory.

Frontage is excited to announce four new strategic positions have been filled to support expanding clinical operations in Secaucus, NJ. Each new acquisition has a doctorate degree with extensive experience and will bring core strengths to Frontage’s growing team.

Exton, PA – October 13, 2015 – Frontage, a full service contract research organization (CRO), today announced that it has expanded its service offerings to agricultural chemical companies engaged in developing products that are covered by FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act) and regulated by the United States Environmental Protection Agency (EPA). The EPA recently completed an inspection of the Frontage’s Exton, Pennsylvania facility on September 3, 2015 with no deficiencies identified. The key services now offered to agrochemical companies include pharmacokinetic evaluations of new candidates, metabolism and mass balance studies using radiolabeled compounds, residue assessments, analytical method development/validation and stability evaluations.

Frontage, a full service contract research organization (CRO) located in the USA and China, is pleased to announce the expansion of its bioanalytical laboratories to meet increased demand for its services from existing and new biopharmaceutical clients.

Exton, PA – September 8, 2015 – Frontage, a full service contract research organization (CRO), today announced the appointment of Michael S. Willett, PharmD., RAC as President of its clinical business unit.

Frontage Expands Clinical Operations in Secaucus, NJ

Exton, PA – May 5, 2015 – Frontage, a full service contract research organization (CRO), today announced the opening of its newest facility in Secaucus, NJ to expand its clinical research portfolio of services.

Exton, P.A. – September 9, 2014 – Frontage Labs has received a grant award of $2.44m from the New Jersey Economic Development Authority. As part of Grow New Jersey Assistance Program, the incentive grant will be used for construction and capital investments involving a 36,000 square foot facility in Secaucus, NJ; to support Phase I-III clinical research.

Exton, P.A. – August 22, 2014 – Frontage today announced recognition by INC Magazine in the INC 5000. For the second time in three years, Frontage earned a spot on the magazine’s thirty-third annual compilation of America’s fastest-growing privately-held companies. Qualifying organizations must demonstrate consistent year-on-year revenue growth and future potential success. In the past three years, the company has achieved nearly 50% revenue growth and added close to 100 new positions. Among companies listed in the greater Philadelphia area, Frontage ranked sixteenth position for new jobs creation.